C00-C97
Conditions
Interventions
Group 1: Carry out at least two PET/MRI examinations: 1x basic examination before the start of therapy + 1x in the follow-up for therapy monitoring.
Sponsors
Universitätsklinikum Tübingen
Eligibility
Sex/Gender
All
Age
6 Months to 17 Years
Inclusion criteria
Inclusion criteria: Children or adolescents <18 years of age for whom the PET/MRI examination is carried out for the following indications: • PET/MRI examination for clinical indication for tumor search (e.g. FUO) • PET/MRI examination for clinical indication for primary staging or re-staging in Hodgin's lymphoma • PET/MRI examination for clinical indication for primary staging or re-staging after therapy in histologically proven, advanced malignant solid tumors (e.g. bone and soft tissue tumors, CNS tumors, neuroblastomas, germ cell tumors) • PET/MRI examination in the case of unclear or inconspicuous imaging for therapy planning (OP, RT, Ctx) and prognosis stratification • PET/MRI examination for re-staging in neurofibromatosis type I with the question of a malignant transformation of the neurofibromas and for biopsy or surgery planning • Written consent of the legal guardian and, if applicable, the child (depending on the individual stage of development) to participate in the study and to report so-called incidental findings after detailed explanation
Exclusion criteria
Exclusion criteria: • Presence of non-MRI-compatible implants or any kind of metal in and on the body (e.g. pacemakers, artificial heart valves, metal prostheses, implanted, magnetic metal parts, coils, etc.) • Children and adolescents who report a hearing disorder or an increased sensitivity to loud noises • Children and adolescents with reduced temperature sensation and/or increased sensitivity to warming of the body • pregnancy • Diabetes mellitus that cannot be controlled with medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The study is primarily used for quality assurance and optimization of PET/MRI examinations in pediatric oncology. For PET/fMRI hybrid imaging, the clinical benefit for children and adolescents with solid tumors is to be determined. The clinical benefit is defined here as a change in patient management (diagnostic and therapeutic) based on the PET/MRI examination. | — |
Secondary
| Measure | Time frame |
|---|---|
| The data should be used to optimize the PET/MRI examination protocols with regard to possible time and dose reductions. | — |
Countries
Germany
Contacts
Public ContactJürgen Schäfer
Radiologische Universitätsklinik Tübingen Diagnostische & Interventionelle Radiologie, Kinderradiologie
Outcome results
None listed